Treatment of invasive aspergillosis: A systematic review of randomized clinical trials

Journal of Invasive Fungal Infections

Volumn 4, Issue 1, 2010, Pages 18-25

  Pasqualotto, Alessandro C ^a   Colombo, Arnaldo L ^b  

^a Santa Casa Complexo Hospitalar   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; MICAFUNGIN; PLACEBO; POSACONAZOLE; TERBINAFINE; VORICONAZOLE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASPERGILLUS; ASPERGILLUS TERREUS; CHILL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG SOLUBILITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEVER; HEMATOLOGIC MALIGNANCY; HOSPITALIZATION; HUMAN; INFUSION RELATED REACTION; INVASIVE ASPERGILLOSIS; KIDNEY FAILURE; MEDLINE; MONOTHERAPY; NEPHROTOXICITY; NEUTROPENIA; OPTIMAL DRUG DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 83455224381     PISSN: 17533783     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Baddley JW, Stroud TP, Salzman D et al. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001;32:1319-24. (Pubitemid 32405904)
2. Boutboul F, Alberti C, Leblanc T et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: increasing antigenemia is associated with progressive disease. Clin Infect Dis 2002;34:939-43. (Pubitemid 34229762)
3. Guinea J, Torres-Narbona M, Gijón P et al. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 2009; Advanced online publication.
4. Nedel WL, Kontoyiannis DP, Pasqualotto AC. Aspergillosis in patients treated with monoclonal antibodies. Rev Iberoam Micol 2009;26:175-83.
5. Cordonnier C, Ribaud P, Herbrecht R et al. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006;42:955-63.
6. Lewis RE. Polyene antifungal agents. In: Pasqualotto AC, editor. Aspergillosis: from diagnosis to prevention. The Netherlands; Springer, 2010:281-306.
7. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-15. (Pubitemid 34851833)
8. Bowden R, Chandrasekar P, White MH et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002;35:359-66. (Pubitemid 34852563)
9. Pasqualotto AC. Amphotericin B: the higher the dose, the higher the toxicity. Clin Infect Dis 2008;47:1110.
10. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990;12:1147-201.
11. Wingard JR, Herbrecht R, Mauskopf J et al. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. Transpl Infect Dis 2007;9:182-8. (Pubitemid 47231209)
12. Berdichevski RH, Luis LB, Crestana L et al. Amphotericin B-related nephrotoxicity inlow-risk patients. Braz J Infect Dis 2006;10:94-9. (Pubitemid 44194332)
13. Harbarth S, Burke JP, Lloyd JF et al. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002;35:e120-7.
14. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999;29:1402-7. (Pubitemid 30022731)
15. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ 2001;322:579-82. (Pubitemid 32234532)
16. Cornely OA, Maertens J, Bresnik M et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007;44:1289-97. (Pubitemid 46717290)
17. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60. (Pubitemid 351265310)
18. Espinel-Ingroff A, Johnson E, Hockey H et al. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase IIIclinical studies. J Antimicrob Chemother 2008;61:616-20. (Pubitemid 351321136)
19. Denes E, Boumediene A, Durox H et al. Voriconazole concentrations in synovial fluid and bone tissues. J Antimicrob Chemother 2007;59:818-9. (Pubitemid 47073436)
20. Hariprasad SM, Mieler WF, Holz ER et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004;122:42-7. (Pubitemid 38063603)
21. Schwartz S, Ruhnke M, Ribaud P et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood 2005;106:2641-5. (Pubitemid 41510735)
22. Jørgensen KJ, Gøtzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006;1:CD004707.
23. Patterson TF, Boucher HW, Herbrecht R et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005;41:1448-52. (Pubitemid 41579987)
24. Pasqualotto AC, Xavier MO, Andreolla HF et al. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf 2010;9:125-37.
25. Ueda K, Nannya Y, Kumano K et al. Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. Int J Hematol 2009;89:592-9.
26. Leenders AC, Daenen S, Jansen RL et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998;103:205-12. (Pubitemid 28470819)
27. De Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-21.
28. Ellis M, Spence D, de Pauw B et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-12. (Pubitemid 29242412)
29. Walsh TJ, Pappas P, Winston DJ et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-34. (Pubitemid 34438861)
30. Johnson JR. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med 2002;346:1745-7; author reply 1745-7.
31. Denning DW. Comparison of 2 studies of treatment of invasive aspergillosis.Clin Infect Dis 2007;45:1106-8. (Pubitemid 47580366)
32. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis 2007;44:373-9. (Pubitemid 46147619)
33. Aquino VR, Goldani LZ, Pasqualotto AC. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 2007;163:191-202. (Pubitemid 46625370)
34. Subirà M, Martino R, Gómez L, et al. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur J Haematol 2004;72:342-7. (Pubitemid 38520732)
35. Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-63. (Pubitemid 32295443)
36. Fleming RV, Kantarjian HM, Husni R et al. Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma 2001;40:511-20. (Pubitemid 32303242)
37. Kuse ER, Chetchotisakd P, da Cunha CA et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007;369:1519-27. (Pubitemid 46670281)
38. Mora-Duarte J, Betts R, Rotstein C et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-9. (Pubitemid 35461658)
39. Perlin DS, Hope WW. Echinocandins. In: Pasqualotto AC, editor. Aspergillosis: from diagnosis to prevention. The Netherlands: Springer, 2010:263-80.
40. Betts R, Glasmacher A, Maertens J et al. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients. Cancer 2006;106:466-73. (Pubitemid 43100459)
41. Viscoli C, Herbrecht R, Akan H, et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother 2009;64:1274-81.
42. Herbrecht R, Maertens J, Baila L et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant 2010; Advanced online publication.
43. Denning DW, Marr KA, Lau WM et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006;53:337-49. (Pubitemid 44524711)
44. van't Wout JW, Novakova I, Verhagen CA et al. The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B. J Infect 1991;22:45-52.
45. Caillot D, Thiébaut A, Herbrecht R et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007;110:2740-6. (Pubitemid 350250344)
46. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14. (Pubitemid 33152659)
47. Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003;37:S188-224. (Pubitemid 37260462)
48. Kirkpatrick WR, Vallor AC, Mcatee RK et al. Combination therapy with terbinafine and amphotericin B in a rabbit model of experimental invasive aspergillosis. Antimicrob Agents Chemother 2005;49:4751-3. (Pubitemid 41552609)
49. Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 2007;119:772-84. (Pubitemid 46556677)